Authors
David Devos, Caroline Moreau, Jean Christophe Devedjian, Jérome Kluza, Maud Petrault, Charlotte Laloux, Aurélie Jonneaux, Gilles Ryckewaert, Guillaume Garçon, Nathalie Rouaix, Alain Duhamel, Patrice Jissendi, Kathy Dujardin, Florent Auger, Laura Ravasi, Lucie Hopes, Guillaume Grolez, Wance Firdaus, Bernard Sablonnière, Isabelle Strubi-Vuillaume, Noel Zahr, Alain Destée, Jean-Christophe Corvol, Dominik Pöltl, Marcel Leist, Christian Rose, Luc Defebvre, Philippe Marchetti, Z Ioav Cabantchik, Régis Bordet
Publication date
2014/7/10
Journal
Antioxidants & redox signaling
Volume
21
Issue
2
Pages
195-210
Publisher
Mary Ann Liebert, Inc.
Description
Aims: The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a chelation strategy aimed at reducing oxidative damage associated with regional iron deposition without affecting circulating metals. Translational cell and animal models provided concept proofs and a delayed-start (DS) treatment paradigm, the basis for preliminary clinical assessments. Results: For translational studies, we assessed the effect of oxidative insults in mice systemically prechelated with deferiprone (DFP) by following motor functions, striatal dopamine (HPLC and MRI-PET), and brain iron deposition (relaxation-R2*-MRI) aided by spectroscopic measurements of neuronal labile iron (with fluorescence-sensitive iron sensors) and oxidative damage by markers of protein, lipid, and DNA modification. DFP significantly reduced labile iron and biological damage in oxidation-stressed cells and animals, improving motor …
Scholar articles
D Devos, C Moreau, JC Devedjian, J Kluza, M Petrault… - Antioxidants & redox signaling, 2014